Clinical Trials
27
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult Still's Disease
- Conditions
- Still's Disease Adult Onset
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- AO GENERIUM
- Target Recruit Count
- 148
- Registration Number
- NCT06497491
- Locations
- 🇷🇺
State budgetary healthcare institution "Chelyabinsk Regional Clinical Hospital", Chelyabinsk, Chelyabinsk region, Russian Federation
🇷🇺Limited Liability Company "Medical Center "Revma-Med", Kemerovo, Russian Federation
🇷🇺Limited Liability Company "OLLA-MED", Moscow, Russian Federation
A Study of Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy Volunteers
- Conditions
- Allergic Asthma
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- AO GENERIUM
- Target Recruit Count
- 180
- Registration Number
- NCT06494345
- Locations
- 🇷🇺
State budgetary healthcare institution of the city of Moscow "City Clinic No. 2 of the Moscow Health Department", Moscow, Russian Federation
An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- AO GENERIUM
- Target Recruit Count
- 422
- Registration Number
- NCT06488664
- Locations
- 🇷🇺
Limited Liability Company "Available Polyclinic", Murino, Leningrad Region, Russian Federation
🇷🇺Limited Liability Company "Family Clinic No. 4", Korolev, Moscow Region, Russian Federation
🇷🇺Limited Liability Company Medical Center "Azbuka Health", Kazan, Republic Of Tatarstan, Russian Federation
A Safety and Pharmacokinetics Study of Complarate (Tocilizumab Biosimilar Solution) and Actemra® in Healthy Volunteers
- Conditions
- Healthy Volunteers
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- AO GENERIUM
- Target Recruit Count
- 256
- Registration Number
- NCT06488521
- Locations
- 🇷🇺
State budgetary healthcare institution of the city of Moscow "City Clinic No. 2 of the Moscow Health Department", Moscow, Russian Federation
🇷🇺Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov Ministry of Health of Russia, Moscow, Russian Federation
🇷🇺LLC "X Seven Clinical Research", Saint Petersburg, Russian Federation
A Safety and Pharmacokinetic Study of Complarate (Tocilizumab Biosimilar) and Actemra® in Healthy Volunteers
- Conditions
- Healthy Volunteers
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- AO GENERIUM
- Target Recruit Count
- 43
- Registration Number
- NCT06481202
- Locations
- 🇷🇺
Department of Clinical Research, Center for Clinical Drug Research, Moscow, Russian Federation
🇷🇺Federal State Autonomous Educational Institution of Higher Education "First Moscow State Medical University named after I.M. Sechenov" of the Ministry of Health of Russia, Moscow, Russian Federation
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next